Equity Profile

KOD

Kodiak Sciences Inc.

Health CareBiotechnology$1.9B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing innovative treatments for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth will help gauge the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing innovative treatments for eye diseases. As part of the health care sector, its advancements could significantly impact patient care and treatment options in ophthalmology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1 2026, Kodiak reported an EPS of -$0.94, slightly missing expectations. The stock reacted negatively, declining 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the high implied volatility in the options market. However, the lack of analyst estimates adds uncertainty.

Bull Case

If Kodiak can demonstrate improved clinical trial results or unexpected revenue growth, it could lead to a positive reassessment of the stock.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide clear guidance, it may face further stock price declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in assessing the company's financial health and could significantly influence investor sentiment.

What updates will be provided on ongoing clinical trials?

Insights into clinical trial progress could impact future revenue potential and investor confidence in Kodiak's product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Kodiak to improve its clinical trial outcomes, which could lead to better-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 39.1% move, indicating significant uncertainty that may not reflect the company's actual performance.

Kodiak's recent history of surprises suggests that the company could outperform expectations despite recent misses.

Key Risk

If the EPS loss is less than -$0.80, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Kodiak can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

A significant reduction in EPS loss, ideally approaching -$0.80 or better, would confirm a positive outlook.

Bear Confirmed If

An EPS loss exceeding -$1.00 would reinforce concerns about the company's financial trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±39.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential price movement, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.4% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations, history suggests a potential stock increase of around 1.55% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of about 0.11% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timeline for clinical trial results.
2Management's commentary on cost control measures.
3Insights into partnerships or collaborations that may enhance revenue.
4Details on market demand for their products.
5Any changes in guidance for future quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Kodiak Sciences Inc. is a biotechnology company focused on developing innovative treatments for eye diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth will help gauge the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KOD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

-0.51%

Last Quarter Recap

In Q1 2026, Kodiak reported an EPS of -$0.94, slightly missing expectations. The stock reacted negatively, declining 4.82% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the high implied volatility in the options market. However, the lack of analyst estimates adds uncertainty.

Bull Case

If Kodiak can demonstrate improved clinical trial results or unexpected revenue growth, it could lead to a positive reassessment of the stock.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide clear guidance, it may face further stock price declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in assessing the company's financial health and could significantly influence investor sentiment.

What updates will be provided on ongoing clinical trials?

Insights into clinical trial progress could impact future revenue potential and investor confidence in Kodiak's product pipeline.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Kodiak to improve its clinical trial outcomes, which could lead to better-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 39.1% move, indicating significant uncertainty that may not reflect the company's actual performance.

Kodiak's recent history of surprises suggests that the company could outperform expectations despite recent misses.

Key Risk

If the EPS loss is less than -$0.80, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Kodiak can stabilize its financial performance and regain investor confidence.

Bull Confirmed If

A significant reduction in EPS loss, ideally approaching -$0.80 or better, would confirm a positive outlook.

Bear Confirmed If

An EPS loss exceeding -$1.00 would reinforce concerns about the company's financial trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±39.1%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential price movement, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±39.1% while KOD has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

60.4%

Calls (22K)P/C Ratio: 0.43Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kodiak beats expectations, history suggests a potential stock increase of around 1.55% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical patterns indicating an average drop of about 0.11% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timeline for clinical trial results.
2Management's commentary on cost control measures.
3Insights into partnerships or collaborations that may enhance revenue.
4Details on market demand for their products.
5Any changes in guidance for future quarters.